Novocure (Nasdaq:NVCR) today announced organizational changes for its leadership team as it prepares for future growth.
The company said the changes became effective Jan. 17.
Pritesh Shah, Novocure’s chief commercial officer, transitioned into a new role as chief growth officer. His responsibilities include product and portfolio strategy, brand management, launch framework and market access/intelligence. He also holds responsibility for new indications in the U.S.
Dr. Ely Benaim, chief medical officer, stepped down from his role and departed the company. He will partner with Novocure’s executive leadership team to ensure a smooth transition. Dr. Piet Hinoul, currently SVP and head of global medical affairs, takes over in an interim role to ensure business continuity.
Novocure chief science officer Dr. Uri Weinberg now becomes chief innovation officer. His new position includes expanding the potential of the company’s tumor-treating fields therapy. Moshe Giladi, the current SVP of preclinical research, will take over as chief science officer at Novocure.
“We believe the successful readout of LUNAR marks the beginning of a transformational period for Novocure, with multiple pivotal studies near completion and numerous future studies preparing for launch,” said Novocure CEO Asaf Danziger. “Our leadership needs continue to evolve with our anticipated growth. We are committed to ensuring we have the optimal structure to support our employees, the business and the thousands of patients we believe we will soon have the opportunity to treat in a multi-indication future.”
NovoCure designed TTFields as electric fields designed to disrupt cancer cell division. They principally combine with other standard-of-care cancer treatments.
